Literature DB >> 22356926

Treatment of catatonia with amantadine.

William M Hervey1, Jonathan T Stewart, Glenn Catalano.   

Abstract

Catatonia is an episodic syndrome characterized by specific affective, behavioral, and motor symptoms and thought to result from regional abnormalities in neurotransmitter function. Although generally thought to represent a manifestation of schizophrenia or depression, there is strong evidence that it may represent a distinct entity, caused by a number of psychogenic, infectious, iatrogenic, and neurological conditions. The morbidity associated with catatonia is significant, and, in some cases, the condition may be life threatening.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356926     DOI: 10.1097/WNF.0b013e318246ad34

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

1.  Going Back to Kahlbaum's Psychomotor (and GABAergic) Origins: Is Catatonia More Than Just a Motor and Dopaminergic Syndrome?

Authors:  Dusan Hirjak; Katharina M Kubera; R Christian Wolf; Georg Northoff
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

2.  Diagnosis and management of periodic catatonia.

Authors:  William M Hervey; Jonathan T Stewart; Glenn Catalano
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

3.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 4.  A clinical review of the treatment of catatonia.

Authors:  Pascal Sienaert; Dirk M Dhossche; Davy Vancampfort; Marc De Hert; Gábor Gazdag
Journal:  Front Psychiatry       Date:  2014-12-09       Impact factor: 4.157

Review 5.  Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence.

Authors:  Daniel Felipe Ariza-Salamanca; María Gabriela Corrales-Hernández; María José Pachón-Londoño; Isabella Hernández-Duarte
Journal:  Front Mol Neurosci       Date:  2022-09-29       Impact factor: 6.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.